Please complete the CAPTCHA to continue
@dndi.org
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
Eric Chatelain is listed as Head of Drug Discovery, Drugs for Neglected Diseases initiative - DNDi at Drugs for Neglected Diseases initiative - DNDi, based in Geneva, Geneva, Switzerland. AeroLeads shows a work email signal at dndi.org and a matched LinkedIn profile for Eric Chatelain.
Eric Chatelain previously worked as Head of Drug Discovery - Member of the Senior Leadership Team at Drugs For Neglected Diseases Initiative - Dndi and Head of Chagas Discovery & Preclinical Program at Drugs For Neglected Diseases Initiative - Dndi. Eric Chatelain holds Diploma In Management Studies (Dms), Business Administration And Management, General from Huron University, London.
This section adds company-level context without repeating Eric Chatelain's masked contact details.
AeroLeads found 1 current-domain work email signal for Eric Chatelain. Compare company email patterns before reaching out.
• 20 years Research & Development experience gained in different environments: academia, Pharma, not-for-profit Product Development Partnerships (PDP)• Broad expertise and understanding of Drug Discovery and Development processes and management, substantiated with the delivery of pre-clinical / clinical candidates• Proven set-up, implementation and leadership of global multidisciplinary and multicultural project teams• Allrounder with open-minded and critical scientific mindset, coupled with a solid background in infectious diseases, dermatology and oncology
Listed skills include Collaborative R&D, Drug Discovery, Drug Development, International Project Management, and 20 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
Geneva, CH
- Leader of the Translational Drug development platform building for COVID-19 (in vitro, ex vivo, in vivo models, PK modelling, PKPD relationships assessment): Generation of preclinical evidence in support of treatment arms of clinical trial- Joint-Leadership of DNDi entire Discovery/Lead Optimization effort- Responsible for the team that delivered.
Geneva, CH
- Responsible for all activities in Chagas disease portfolio, from discovery to clinical candidate nomination- Led the multinational team that delivered pre-clinical candidates for Chagas disease- Definition with the Head of Clinical Program of the overall public health research strategy for Chagas disease at DNDi
Geneva, CH
- Responsible for all screening/early discovery activities for new drugs for neglected diseases (Human African Trypanosomiasis, Leishmaniasis, Chagas) in DNDi portfolio- Development and implementation of DNDi discovery strategy: transition from a project-based to a more strategic-oriented approach (portfolio) of DNDi screening/discovery activities; HTS in.
- Responsible for all preclinical research activities including the budgeting, planning and coordination with the other R&D departments and CROs, documentation and control- Active member of the R&D and Scientific Advisory Boards, acquainted with all processes, workflows and interfaces involved in project development and interacting with people of all.
- Planning, budgeting and set-up of two new laboratories. Set-up and use of new methods and models for formulation tolerance and efficacy assessment and topical delivery systems screening purposes- Participation together with Novartis, Pfizer, GSK and 3M at inter-laboratory pre-validation studies for the evaluation of the SkinEthic model as possible tool.
Basel, BS, CH
Gene therapy project: Generation of adenoviral constructs as carriers for molecular radiosensitisers under the control of tumor specific promoters. Goal: Increase the radiosensitivity of tumor cells.
London, GB
Investigation of the role of mouse Fibroblast Growth Factor 3 using genetic strategies (specific and conditional knock-out of the fgf3 gene in the mouse involving the Cre-LoxP technology). Structure/function analysis of its specific receptors.
Quick answers generated from the profile data available on this page.
Eric Chatelain works for Drugs for Neglected Diseases initiative - DNDi.
Eric Chatelain is listed as Head of Drug Discovery, Drugs for Neglected Diseases initiative - DNDi at Drugs for Neglected Diseases initiative - DNDi.
AeroLeads has found 1 work email signal at @dndi.org for Eric Chatelain at Drugs for Neglected Diseases initiative - DNDi.
Eric Chatelain is based in Geneva, Geneva, Switzerland while working with Drugs for Neglected Diseases initiative - DNDi.
Eric Chatelain has worked for Drugs For Neglected Diseases Initiative - Dndi, Galderma (Formerly Spirig Pharma Ag), Friedrich Miescher Institute For Biomedical Research (Fmi)/ Novartis Research Foundation, and Cancer Research Uk.
You can use AeroLeads to view verified contact signals for Eric Chatelain at Drugs for Neglected Diseases initiative - DNDi, including work email, phone, and LinkedIn data when available.
Eric Chatelain holds Diploma In Management Studies (Dms), Business Administration And Management, General from Huron University, London.
Eric Chatelain is listed with skills including Collaborative R&D, Drug Discovery, Drug Development, International Project Management, Infectious Diseases, Lead Optimization Process, Translational Research, and Biomarker Discovery.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts